



Anylam Pharmaceuticals, Inc.  
Investor Relations Department  
300 Third Street  
Cambridge, MA 02142  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: ALNY 1

|                   |                          |
|-------------------|--------------------------|
| Last Trade:       | 114.70                   |
| Trade Time:       | 4:15 PM ET<br>10.20.2017 |
| Change:           | -0.93  (0.804%)          |
| Day Range         | 111.25 - 115.74          |
| 52-Week Range     | 31.38 - 126.16           |
| Volume            | 1,310,104                |
| Market Cap. (\$M) | 10,521.431               |
| Shares Out (M)    | 91.730                   |

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Anylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STArS): genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. These novel therapeutics carry the potential to transform the lives of patients who have limited or inadequate treatment options. Founded in 2002, Anylam is delivering on a bold vision to turn scientific possibility into a reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are i ... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 10.20.2017 [Anylam and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors](#)
- 10.18.2017 [Anylam and Vir Form Strategic Alliance to Advance RNAi Therapeutics for Infectious Diseases](#)
- 09.26.2017 [Anylam Initiates Phase 2 Clinical Study of Cemdisiran \(ALN-CC5\) in Patients with Atypical Hemolytic-Uremic Syndrome \(aHUS\)](#)
- 09.25.2017 [Anylam Continues Leadership in RNAi Technologies and Delivery with New Pre-Clinical Data Presented on "Enhanced Stabilization Chemistry Plus" \(ESC+\) GalNAC-siRNA Conjugate Platform at 13th Annual Meeting of the Oligonucleotide Therapeutics Society](#)
- 09.20.2017 [Anylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR \(hATTR\) Amyloidosis Patients with Polyneuropathy](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Second Quarter Financial Results](#)

- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 08.09.2017 [Quarterly Report \(10-Q\)](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)
- 11.03.2016 [Quarterly Report \(10-Q\)](#)

